Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Design considerations and analytical framework for reliably identifying a beneficial individualized treatment rule

Contemporary Clinical Trials(2022)10.1016/j.cct.2022.106951Source: DataRank Database

Design considerations and analytical framework for reliably identifying a beneficial individualized treatment rule is a research paper published in Contemporary Clinical Trials (2022). On theSindex it has a DataRank of 0.165. It has been cited 2 times.

N/A

0.165DataRank · unranked

Scored on demand from live citation data

2 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 0.44)OA: closedTopics (24)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.165

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (7)

Thomas A. Murray ORCID,Kyle Rudser ORCID,Alexander J. Rothman ORCID,Anne C. Melzer ORCID,Anne M. Joseph ORCID

Live enrichment

PubMed:36241146 OpenAlex:https://openalex.org/W4304689592

National Institute on Drug Abuse

Grant: R01DA046320

National Cancer Institute

Grant: P30-CA0077598

National Cancer Institute

Grant: R01CA196873

National Cancer Institute

Grant: R01CA214825

National Cancer Institute

Grant: R01CA225190

National Center for Advancing Translational Sciences

Grant: UL1TR002494

Medtronic

National Institutes of Health

FWCI

0.44

Citation Percentile

0.6%

Citation Trend

2024

closedLicense: https://doi.org/10.15223/policy-004

publisherhttps://api.elsevier.com/content/article/PII:S1551714422002774?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1551714422002774?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cct.2022.106951

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36241146

Fields of Study

Statistical Methods in Clinical TrialsAdvanced Causal Inference TechniquesGenetic Associations and EpidemiologyHumansBeesAnimalsPrecision Medicine

MeSH Terms

AnimalsBeesHumansPrecision Medicine

Keywords

Sample size determinationMedicineIdentification (biology)Personalized medicineSample (material)Function (biology)Computer scienceStatisticsMathematicsBioinformaticsClinical TrialsLassoIndividualized Treatment Rule

Sustainable Development Goals

SDG 0: Good health and well-being